Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester, discusses interim results from a study testing mezagitamab for the treatment of immunoglobulin A (IgA) nephropathy.
IgA nephropathy is a kidney disorder that occurs when IgA protein settles in the kidneys. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. End-stage kidney disease may develop. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver, celiac disease, and HIV infection.
Mezagitamab (TAK-079) is an investigational fully human, anti-CD38 monoclonal antibody. The compound is designed to decrease formation of immune complexes, reduce inflammation and resulting proteinuria, and prevent further kidney injury and promote stabilization of kidney function.
Mezagitamab is currently being evaluated as an add-on to stable background therapy for IgAN in a phase 1b, open-label, single-arm, multicenter clinical trial (NCT05174221). Interim data from this proof-of-concept study was recently presented at the American Society of Nephrology (ASN) Kidney Week 2025.
Through week 96, mezagitamab stabilized kidney function with a 55.2% sustained mean reduction in proteinuria as measured by a urine protein-creatinine ratio (UPCR). A sustained reduction of 50.1% in Gd-IgA1 and complete recovery toward baseline IgG were also observed. Additionally, hematuria was resolved in 60% of patients.
Mezagitamab was generally well tolerated with no new safety concerns identified. No serious adverse events, discontinuations due to adverse events, or infections greater than grade 3 were reported.
For more information, click here.
To learn more about IgAN and other rare kidney diseases, visit https://checkrare.com/diseases/kidney-and-urinary-diseases/